Viviana Garcia-Horton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Viviana Garcia-Horton has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Mirko Fillbrunn
Analysis Group, Inc., Boston, MA
2 shared publications- Paul Feuerstadt
Department of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
2 shared publications Adam Harvey
Rebiotix, a Ferring Company, Roseville, USA
1 shared publicationAdrianus Reginald Waldeck
Bayer, Whippany,NJ07981,USA
1 shared publicationAhmad A Tarhini
Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
1 shared publicationAmy Guo
Ferring Pharmaceuticals, Inc, Parsippany, USA
1 shared publication
Latest Publications
- Open Access
- 14 December 2025
- Published by BMJ in BMJ Oncology
- Vol. 4 (1) , e000912
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF -mutant advanced melanoma: A matching-adjusted indirect comparison
Background: Dual immuno-oncology (IO) therapy or BRAF/MEK inhibitor combinations are approved first-line (1L) treatment options for BRAF- mutant advanced melanoma. In the absence of head-to-head trials comparing 1L nivolumab plus relatlimab (NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vemurafenib+cobimetinib (VEM+COBI) and atezolizumab (ATEZO)+VEM+COBI using matching-adjusted indirect comparisons (MAICs). Methods: Patient-level data for NIVO+RELA from the RELATIVITY-047 trial ( BRAF -mutant subset) and aggregate data from the COMBI-d/v, COLUMBUS, coBRIM and IMspire150 trials were used. Adults with untreated BRAF- mutant advanced melanoma receiving 1L therapy were included. Separate unanchored MAICs were conducted to compare outcomes between NIVO+RELA versus comparators. MAICs matched on baseline characteristics per data availability and clinical relevance (age, sex, metastatic stage, prior IO, brain metastases, tumour size, etc.). Overall survival (OS) and investigator-assessed progression-free survival (PFS) were compared using weighted Cox proportional hazards models and, due to violation of the proportional hazards assumption, interval Cox models with boundaries at 12 (doublets) or 24 (ATEZO+VEM+COBI) months from treatment initiation. Investigator-assessed overall response rate (ORR) and safety outcomes (any adverse event (AE), grade 3/4 AEs, AEs leading to discontinuation, specific AEs) were compared via ORs and risk differences (RDs), respectively. Results: BRAF -mutant patients from RELATIVITY-047 (n=136) were matched to patients who received DAB+TRAM (n=563), ENCO+BINI (n=192), VEM+COBI (n=247) or ATEZO+VEM+COBI (n=256). Post-matching, NIVO+RELA was associated with longer OS after 12 months versus DAB+TRAM (HR (95% CI) 0.47 (0.31 to 0.70)), ENCO+BINI (0.51 (0.32 to 0.83)) and VEM+COBI (0.41 (0.26 to 0.62)) and at any time versus ATEZO+VEM+COBI (0.68 (0.48–0.98)). PFS was shorter versus DAB+TRAM (1.36 (0.96 to 1.94)), ENCO+BINI (1.72 (1.13 to 2.61)) and VEM+COBI (1.27 (0.89 to 1.81)) in the first 12 months but favoured NIVO+RELA after 12 months (0.56 (0.33 to 0.93), 0.63 (0.28 to 1.45) and 0.41 (0.24 to 0.70)). PFS was similar versus ATEZO+VEM+COBI through 24 months (1.21 (0.87 to 1.68)) and favoured NIVO+RELA beyond 24 months (0.45 (0.19 to 1.07)). ORR was lower with NIVO+RELA versus all comparators. Grade 3/4 AEs were less frequent with NIVO+RELA versus DAB+TRAM (RD (95% CI) −20.1% (−30.6 to −9.5)), ENCO+BINI (−29.2% (-42.2 to −16.3)), VEM+COBI (−36.9% (−47.5 to −26.3)) and ATEZO+VEM+COBI (percentage: 40.0% vs 74.9%). Conclusions: These MAICs suggest that 1L dual IO therapy with NIVO+RELA confers a long-term OS advantage in BRAF -mutant advanced melanoma compared with BRAF/MEK inhibitor combinations despite lower ORR, consistent with prior evidence for 1L NIVO+IPI in this setting. As unanchored analyses, potential residual confounding remains, and results should be interpreted cautiously.
- 14 December 2025
- Published by BMJ in BMJ Oncology
- Vol. 4 (1) , e000912
Open AccessEfficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF -mutant advanced melanoma: A matching-adjusted indirect comparison
Background: Dual immuno-oncology (IO) therapy or BRAF/MEK inhibitor combinations are approved first-line (1L) treatment options for BRAF- mutant advanced melanoma. In the absence of head-to-head trials comparing 1L nivolumab plus relatlimab (NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vemurafenib+cobimetinib (VEM+COBI) and atezolizumab (ATEZO)+VEM+COBI using matching-adjusted indirect comparisons (MAICs). Methods: Patient-level data for NIVO+RELA from the RELATIVITY-047 trial ( BRAF -mutant subset) and aggregate data from the COMBI-d/v, COLUMBUS, coBRIM and IMspire150 trials were used. Adults with untreated BRAF- mutant advanced melanoma receiving 1L therapy were included. Separate unanchored MAICs were conducted to compare outcomes between NIVO+RELA versus comparators. MAICs matched on baseline characteristics per data availability and clinical relevance (age, sex, metastatic stage, prior IO, brain metastases, tumour size, etc.). Overall survival (OS) and investigator-assessed progression-free survival (PFS) were compared using weighted Cox proportional hazards models and, due to violation of the proportional hazards assumption, interval Cox models with boundaries at 12 (doublets) or 24 (ATEZO+VEM+COBI) months from treatment initiation. Investigator-assessed overall response rate (ORR) and safety outcomes (any adverse event (AE), grade 3/4 AEs, AEs leading to discontinuation, specific AEs) were compared via ORs and risk differences (RDs), respectively. Results: BRAF -mutant patients from RELATIVITY-047 (n=136) were matched to patients who received DAB+TRAM (n=563), ENCO+BINI (n=192), VEM+COBI (n=247) or ATEZO+VEM+COBI (n=256). Post-matching, NIVO+RELA was associated with longer OS after 12 months versus DAB+TRAM (HR (95% CI) 0.47 (0.31 to 0.70)), ENCO+BINI (0.51 (0.32 to 0.83)) and VEM+COBI (0.41 (0.26 to 0.62)) and at any time versus ATEZO+VEM+COBI (0.68 (0.48–0.98)). PFS was shorter versus DAB+TRAM (1.36 (0.96 to 1.94)), ENCO+BINI (1.72 (1.13 to 2.61)) and VEM+COBI (1.27 (0.89 to 1.81)) in the first 12 months but favoured NIVO+RELA after 12 months (0.56 (0.33 to 0.93), 0.63 (0.28 to 1.45) and 0.41 (0.24 to 0.70)). PFS was similar versus ATEZO+VEM+COBI through 24 months (1.21 (0.87 to 1.68)) and favoured NIVO+RELA beyond 24 months (0.45 (0.19 to 1.07)). ORR was lower with NIVO+RELA versus all comparators. Grade 3/4 AEs were less frequent with NIVO+RELA versus DAB+TRAM (RD (95% CI) −20.1% (−30.6 to −9.5)), ENCO+BINI (−29.2% (-42.2 to −16.3)), VEM+COBI (−36.9% (−47.5 to −26.3)) and ATEZO+VEM+COBI (percentage: 40.0% vs 74.9%). Conclusions: These MAICs suggest that 1L dual IO therapy with NIVO+RELA confers a long-term OS advantage in BRAF -mutant advanced melanoma compared with BRAF/MEK inhibitor combinations despite lower ORR, consistent with prior evidence for 1L NIVO+IPI in this setting. As unanchored analyses, potential residual confounding remains, and results should be interpreted cautiously.
- Open Access
- 22 June 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (12) , 897-909.e8
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- 22 June 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (12) , 897-909.e8
Open AccessIndirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- Open Access
- 18 January 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (1) , 221-236
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
Introduction Clostridioides difficile infection (CDI) causes symptoms of varying severity and negatively impacts patients’ health-related quality of life (HRQL). Despite antibiotic treatment, recurrence of CDI (rCDI) is common and imposes clinical and economic burdens on patients. Fecal microbiota, live-jslm (REBYOTA [RBL]) is newly approved in the USA for prevention of rCDI following antibiotic treatments. We analyzed efficacy and HRQL impact of RBL vs. placebo in patients at first rCDI using data from the phase 3 randomized, double-blind placebo-controlled clinical trial, PUNCH CD3. Methods This post hoc analysis included patients at first rCDI fromPUNCH CD3. Treatment success (i.e., absence of diarrhea within 8 weeks post-treatment) was analyzed adjusting for baseline patient characteristics. HRQL was measured using the Clostridioides difficile Quality of Life Survey (Cdiff32); absolute scores and change from baseline in total and domain (physical, mental, and social) scores were summarized and compared between arms. Analyses were conducted for the trial’s blinded phase only. Results Among 86 eligible patients (32.8% of the overall trial population, RBL 53 [61.6%], placebo 33 [38.4%]), RBL-treated patients had significantly lower odds of recurrence (i.e., greater probability of treatment success) at week 8 vs. placebo (odds ratio 0.35 [95% confidence interval 0.13, 0.98]). Probability of treatment success at week 8 was 81% for RBL and 60% for placebo, representing 21% absolute and 35% relative increases for RBL (crude proportions 79.2% vs. 60.6%; relative risk 0.53, p = 0.06). Additionally, RBL was associated with significantly higher Cdiff32 total (change score difference 13.5 [standard deviation 5.7], p < 0.05) and mental domain (16.2 [6.0], p < 0.01) scores vs. placebo from baseline to week 8. Conclusion Compared to placebo, RBL demonstrated a significantly higher treatment success in preventing further rCDI and enhanced HRQL among patients at first recurrence, establishing RBL as an effective treatment to prevent further recurrences in these patients. Trial Registration ClinicalTrials.gov Identifier NCT03244644.
- 18 January 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (1) , 221-236
Open AccessEfficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
Introduction Clostridioides difficile infection (CDI) causes symptoms of varying severity and negatively impacts patients’ health-related quality of life (HRQL). Despite antibiotic treatment, recurrence of CDI (rCDI) is common and imposes clinical and economic burdens on patients. Fecal microbiota, live-jslm (REBYOTA [RBL]) is newly approved in the USA for prevention of rCDI following antibiotic treatments. We analyzed efficacy and HRQL impact of RBL vs. placebo in patients at first rCDI using data from the phase 3 randomized, double-blind placebo-controlled clinical trial, PUNCH CD3. Methods This post hoc analysis included patients at first rCDI fromPUNCH CD3. Treatment success (i.e., absence of diarrhea within 8 weeks post-treatment) was analyzed adjusting for baseline patient characteristics. HRQL was measured using the Clostridioides difficile Quality of Life Survey (Cdiff32); absolute scores and change from baseline in total and domain (physical, mental, and social) scores were summarized and compared between arms. Analyses were conducted for the trial’s blinded phase only. Results Among 86 eligible patients (32.8% of the overall trial population, RBL 53 [61.6%], placebo 33 [38.4%]), RBL-treated patients had significantly lower odds of recurrence (i.e., greater probability of treatment success) at week 8 vs. placebo (odds ratio 0.35 [95% confidence interval 0.13, 0.98]). Probability of treatment success at week 8 was 81% for RBL and 60% for placebo, representing 21% absolute and 35% relative increases for RBL (crude proportions 79.2% vs. 60.6%; relative risk 0.53, p = 0.06). Additionally, RBL was associated with significantly higher Cdiff32 total (change score difference 13.5 [standard deviation 5.7], p < 0.05) and mental domain (16.2 [6.0], p < 0.01) scores vs. placebo from baseline to week 8. Conclusion Compared to placebo, RBL demonstrated a significantly higher treatment success in preventing further rCDI and enhanced HRQL among patients at first recurrence, establishing RBL as an effective treatment to prevent further recurrences in these patients. Trial Registration ClinicalTrials.gov Identifier NCT03244644.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
Recurrence of Clostridioides difficile infection (rCDI) substantially diminishes patients’ health-related quality of life (HRQL). The gut microbiome is known to play an important role in rCDI, but little is known about its relationship with HRQL. In this study, we assessed the relationship between the gut microbiome and HRQL in patients with rCDI from REBYOTA’s (fecal microbiota, live-jslm [RBL]) phase 3 PUNCH CD3 trial (NCT03244644). HRQL and relative abundance (i.e., the % of one microbiota relative to all other analyzed) of gut microbiota at the class level were collected at baseline and weeks 1, 4, and 8. The Microbiome Health Index (MHI; Blount et al, 2022), defined as (Bacteroidia + Clostridia) / (Gammaproteobacteria + Bacilli), was analyzed using log transformation and as a binary indicator with MHI > 7.2 indicating a healthy microbiome. HRQL was measured using the disease-specific C. difficile Quality of Life Survey (Cdiff32) via its total score and physical, mental, and social domain scores (0–100 range, 100 best). Correlations between microbiota data (Bacteroidia, Clostridia, Gammaproteobacteria, Bacilli, and log MHI) and Cdiff32 scores were estimated. Associations of Cdiff32 scores with microbiota data and MHI > 7.2 were estimated using mixed effects analyses adjusted for baseline patient characteristics. Analyses used all available data (baseline, weeks 1, 4, 8). P-values were adjusted for multiple testing via the Benjamini-Hochberg procedure; correlations were interpreted as moderate if ≥ 0.3 and large if ≥ 0.5 (Cohen, 1988). Our study found moderate to large and statistically significant associations between a healthy gut microbiome and improved HRQL in patients with rCDI. Paul Feuerstadt, MD, FACG, AGAF, Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant|Ferring/Rebiotix Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Seres Therapeutics: Advisor/Consultant|Seres Therapeutics: Grant/Research Support|Takeda Pharmaceuticals: Advisor/Consultant Ken Blount, PhD, Ferring Pharmaceuticals: Employee Amy Guo, PhD, Ferring Pharmaceuticals: Employee Min Yang, MD, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Viviana García-Horton, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Mirko Fillbrunn, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Glenn S. Tillotson, PhD, Dynavax: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Peggy Lillis Foundation: Honoraria|Spero Therapeutics: Advisor/Consultant Yipeng Gao, PhD, Merck and Co.: Grant/Research Support Erik R. Dubberke, MD, MSPH, Abbott: Advisor/Consultant|AstraZeneca: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Ferring Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Seres Therapeutics: Advisor/Consultant|Summit: Advisor/Consultant|Theriva Biologics: Grant/Research Support Kevin W. Garey, PharmD, MS, Acurx: Grant/Research Support|Ferring: Advisor/Consultant|Paratek: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
Recurrence of Clostridioides difficile infection (rCDI) substantially diminishes patients’ health-related quality of life (HRQL). The gut microbiome is known to play an important role in rCDI, but little is known about its relationship with HRQL. In this study, we assessed the relationship between the gut microbiome and HRQL in patients with rCDI from REBYOTA’s (fecal microbiota, live-jslm [RBL]) phase 3 PUNCH CD3 trial (NCT03244644). HRQL and relative abundance (i.e., the % of one microbiota relative to all other analyzed) of gut microbiota at the class level were collected at baseline and weeks 1, 4, and 8. The Microbiome Health Index (MHI; Blount et al, 2022), defined as (Bacteroidia + Clostridia) / (Gammaproteobacteria + Bacilli), was analyzed using log transformation and as a binary indicator with MHI > 7.2 indicating a healthy microbiome. HRQL was measured using the disease-specific C. difficile Quality of Life Survey (Cdiff32) via its total score and physical, mental, and social domain scores (0–100 range, 100 best). Correlations between microbiota data (Bacteroidia, Clostridia, Gammaproteobacteria, Bacilli, and log MHI) and Cdiff32 scores were estimated. Associations of Cdiff32 scores with microbiota data and MHI > 7.2 were estimated using mixed effects analyses adjusted for baseline patient characteristics. Analyses used all available data (baseline, weeks 1, 4, 8). P-values were adjusted for multiple testing via the Benjamini-Hochberg procedure; correlations were interpreted as moderate if ≥ 0.3 and large if ≥ 0.5 (Cohen, 1988). Our study found moderate to large and statistically significant associations between a healthy gut microbiome and improved HRQL in patients with rCDI. Paul Feuerstadt, MD, FACG, AGAF, Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant|Ferring/Rebiotix Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Seres Therapeutics: Advisor/Consultant|Seres Therapeutics: Grant/Research Support|Takeda Pharmaceuticals: Advisor/Consultant Ken Blount, PhD, Ferring Pharmaceuticals: Employee Amy Guo, PhD, Ferring Pharmaceuticals: Employee Min Yang, MD, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Viviana García-Horton, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Mirko Fillbrunn, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Glenn S. Tillotson, PhD, Dynavax: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Peggy Lillis Foundation: Honoraria|Spero Therapeutics: Advisor/Consultant Yipeng Gao, PhD, Merck and Co.: Grant/Research Support Erik R. Dubberke, MD, MSPH, Abbott: Advisor/Consultant|AstraZeneca: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Ferring Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Seres Therapeutics: Advisor/Consultant|Summit: Advisor/Consultant|Theriva Biologics: Grant/Research Support Kevin W. Garey, PharmD, MS, Acurx: Grant/Research Support|Ferring: Advisor/Consultant|Paratek: Grant/Research Support
- Open Access
- 2 October 2023
- Vol. 13 (5) , 207-216
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia.
Deutetrabenazine is approved for treatment of Huntington disease (HD)-related chorea and tardive dyskinesia (TD) in adults. Factors associated with deutetrabenazine persistence and adherence are not well understood. Claims data from the Symphony Health Solutions Integrated Dataverse (2017-2019) were analyzed to identify real-world predictors of deutetrabenazine persistence and adherence in adults with HD or TD in the United States. Predictive models for persistence and adherence that considered patient demographics, payer type, comorbidities, treatment history, and health care resource use were developed. In HD, use of anticonvulsants (HR = 2.00 [95% CI = 1.03, 3.85]; P < .05), lipid-lowering agents (2.22 [1.03, 4.76]; P < .05), and Medicaid versus Medicare insurance (2.27 [1.03, 5.00]; P < .05) predicted persistence, whereas only comorbid anxiety disorders predicted discontinuation (0.46 [0.23, 0.93]; P < .05). Of these patients, 62.5% were adherent at 6 months. Use of ≤2 treatments for chronic diseases (OR = 0.18 [95% CI = 0.04, 0.81]; P < .05) and Medicaid versus Medicare insurance (0.27 [0.09, 0.75]; P < .05) was associated with lower odds of adherence. In TD, use of lipid-lowering agents (HR = 4.76 [95% CI = 1.02, 20.00]; P < .05) predicted persistence, while comorbid schizoaffective disorder and/or schizophrenia (0.16 [0.14, 0.69]; P < .05) and sleep-wake disorders (0.18 [0.04, 0.82]; P < .05) predicted discontinuation. Of these patients, 46.7% were adherent at 6 months. Comorbid schizoaffective disorder and/or schizophrenia was associated with lower odds of adherence (OR = 0.26 [0.07, 0.91]; P < .05). Identifying factors predictive of discontinuation and/or nonadherence to deutetrabenazine may facilitate the development of personalized support programs that seek to improve outcomes in patients with HD or TD.
- 2 October 2023
- Vol. 13 (5) , 207-216
Open AccessPredictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia.
Deutetrabenazine is approved for treatment of Huntington disease (HD)-related chorea and tardive dyskinesia (TD) in adults. Factors associated with deutetrabenazine persistence and adherence are not well understood. Claims data from the Symphony Health Solutions Integrated Dataverse (2017-2019) were analyzed to identify real-world predictors of deutetrabenazine persistence and adherence in adults with HD or TD in the United States. Predictive models for persistence and adherence that considered patient demographics, payer type, comorbidities, treatment history, and health care resource use were developed. In HD, use of anticonvulsants (HR = 2.00 [95% CI = 1.03, 3.85]; P < .05), lipid-lowering agents (2.22 [1.03, 4.76]; P < .05), and Medicaid versus Medicare insurance (2.27 [1.03, 5.00]; P < .05) predicted persistence, whereas only comorbid anxiety disorders predicted discontinuation (0.46 [0.23, 0.93]; P < .05). Of these patients, 62.5% were adherent at 6 months. Use of ≤2 treatments for chronic diseases (OR = 0.18 [95% CI = 0.04, 0.81]; P < .05) and Medicaid versus Medicare insurance (0.27 [0.09, 0.75]; P < .05) was associated with lower odds of adherence. In TD, use of lipid-lowering agents (HR = 4.76 [95% CI = 1.02, 20.00]; P < .05) predicted persistence, while comorbid schizoaffective disorder and/or schizophrenia (0.16 [0.14, 0.69]; P < .05) and sleep-wake disorders (0.18 [0.04, 0.82]; P < .05) predicted discontinuation. Of these patients, 46.7% were adherent at 6 months. Comorbid schizoaffective disorder and/or schizophrenia was associated with lower odds of adherence (OR = 0.26 [0.07, 0.91]; P < .05). Identifying factors predictive of discontinuation and/or nonadherence to deutetrabenazine may facilitate the development of personalized support programs that seek to improve outcomes in patients with HD or TD.
- Open Access
- 16 February 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (5) , 385-395
Safety Differences Across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Approval of apalutamide, enzalutamide and darolutamide has transformed the treatment landscape and guideline recommendations for patients with nonmetastatic castration-resistant prostate cancer but... Plain language summary Prostate cancer is one of the most common cancers in men. Because male hormones fuel the growth of prostate cancer cells, initial treatments generally focus on reducing these... Tweetable abstract Key safety differences exist among second-generation androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer. We discuss these differences and their p...
- 16 February 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (5) , 385-395
Open AccessSafety Differences Across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Approval of apalutamide, enzalutamide and darolutamide has transformed the treatment landscape and guideline recommendations for patients with nonmetastatic castration-resistant prostate cancer but... Plain language summary Prostate cancer is one of the most common cancers in men. Because male hormones fuel the growth of prostate cancer cells, initial treatments generally focus on reducing these... Tweetable abstract Key safety differences exist among second-generation androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer. We discuss these differences and their p...